Print

Purpose

This is a Phase 3, 2-arm, multicenter study with an open-label ivacaftor arm and an observational arm to evaluate the safety and efficacy of long-term ivacaftor treatment in participants with cystic fibrosis (CF) who are <24 months of age at treatment initiation and have an approved Ivacaftor-Responsive mutation.

Condition

Eligibility

Eligible Ages
Between 0 Months and 24 Months
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

Ivacaftor Arm: Participants From Study 124 (NCT02725567 ) Part B: - Participants transitioning from Study 124 Part B must have completed the last study visit of Study 124 Part B. - As judged by the investigator, parent or legal guardian must be able to understand protocol requirements, restrictions, and instructions; and must sign the informed consent form (ICF). Ivacaftor Arm: Participants Not From Study 124 Part B: - Confirmed diagnosis of CF, or 2 CF-causing mutations. - An ivacaftor- responsive CFTR mutation on at least 1 allele. Participants will be eligible in countries/regions where ivacaftor is approved for use in participants 2 years of age and older. - As judged by the investigator, parent or legal guardian must be able to understand protocol requirements, restrictions, and instructions; and must sign the ICF. Observational Arm: - Received ivacaftor treatment in Study 124 Part B and elected not to enroll or ineligible to enroll in the ivacaftor arm of Study 126.

Exclusion Criteria

Ivacaftor Arm: Participants From Study 124 Part B: - History of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering ivacaftor to the participant. - Participants receiving commercially available ivacaftor treatment Ivacaftor Arm: Participants Not From Study 124 Part B: - History of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering ivacaftor to the participant - An acute upper or lower respiratory infection, or pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks of Day 1 - Abnormal liver function at screening - Hemoglobin <9.5 g/dL at screening - History of solid organ or hematological transplantation - Use of any moderate or strong inducers or inhibitors of CYP3A within 2 weeks of Day 1 Observational Arm: - Receiving ivacaftor treatment Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Ivacaftor Arm 		Participants less than (<) 24 months of age and weighing 5 to less than (<) 7 kilogram (kg) received 25 mg IVA every 12 hours (q12h), 7 to <14 kg received 50 mg IVA q12h, and those weighing 14 to <25 kg received 75 mg IVA q12h. Participants more than or equal (>=) 24 months of age and weighing <14 kg received 50 mg IVA q12h, and those weighing more than or equal to (>=)14 kg received 75 mg IVA q12h in the treatment period for up to 96 weeks. Doses were determined based on safety and pharmacokinetic (PK) data from parent study, age and weight.
  • Drug: IVA
    Granules for oral administration.
    Other names:
    • VX-770
    • ivacaftor
No Intervention
Observational Arm

More Details

Status
Completed
Sponsor
Vertex Pharmaceuticals Incorporated

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.